Former Chinese Nationalist Party (KMT) vice chairman Hau Lung-bin (郝龍斌) is to appeal the Food and Drug Administration’s (FDA) authorization of Medigen Vaccine Biologics’ COVID-19 vaccine, he said yesterday.
The administration on July 19 granted Medigen emergency use authorization, even though the drugmaker had not yet completed phase 3 clinical trials.
The government should not authorize the use of a vaccine that has not completed phase 3 trials, Hau said in Taipei on the sidelines of an event to distribute boxed meals with former president Ma Ying-jeou (馬英九) and Broadcasting Corp of China chairman Jaw Shaw-kong (趙少康).
Photo: Fang Pin-chao, Taipei Times
Hau said the government had politicized science in its hasty approval of a domestically developed COVID-19 vaccine.
The emergency use authorization of a vaccine prior to the completion of phase 3 trials is unprecedented, as it means a vaccine’s efficacy has not been verified, he said, adding that President Tsai Ing-wen (蔡英文) and Vice President William Lai (賴清德) have set a poor example in saying they would take the Medigen vaccine.
“The government should spare the lives of the Taiwanese people,” he said.
Minister of Health and Welfare Chen Shih-chung (陳時中), who heads the Central Epidemic Command Center, yesterday said that the center respects the right of citizens to file petitions related to the authorization.
Medigen is the only Taiwanese company to which the FDA has granted emergency use authorization.
The administration said it based its decision on data Medigen obtained in a phase 2 clinical trial of about 4,000 participants earlier this year, which was analyzed through immunobridging and compared with a control group of 200 recipients of the AstraZeneca COVID-19 vaccine in Taoyuan.
Immunobridging is a method to infer the efficacy of a vaccine by comparing the concentration of neutralizing antibodies in each group of recipients with that of an approved vaccine.
Medigen on July 20 announced that it had received permission to conduct a 1,000-person phase 3 clinical trial in Paraguay for its COVID-19 vaccine.
Participants in the trial, to be held with the National University of Asuncion’s medical school, would be recruited in the third quarter of this year and Medigen expects to have interim analysis data in the fourth quarter, the company said.
The trial would compare recipients of the Medigen and AstraZeneca vaccines through immunobridging, it said.
Medigen did not elaborate on its reasons for holding such a small trial or its use of immunobridging, which has been criticized as an insufficient substitute for traditional efficacy data.
Taiwan has agreed to buy 10 million doses of COVID-19 vaccines from two Taiwanese manufacturers: Medigen and United Biomedical, which has not yet been granted emergency use authorization by the FDA.
LOUD AND PROUD Taiwan might have taken a drubbing against Australia and Japan, but you might not know it from the enthusiasm and numbers of the fans Taiwan might not be expected to win the World Baseball Classic (WBC) but their fans are making their presence felt in Tokyo, with tens of thousands decked out in the team’s blue, blowing horns and singing songs. Taiwanese fans have packed out the Tokyo Dome for all three of their games so far and even threatened to drown out home team supporters when their team played Japan on Friday. They blew trumpets, chanted for their favorite players and had their own cheerleading squad who dance on a stage during the game. The team struggled to match that exuberance on the field, with
If China chose to invade Taiwan tomorrow, it would only have to sever three undersea fiber-optic cable clusters to cause a data blackout, Jason Hsu (許毓仁), a senior fellow at the Hudson Institute and former Chinese Nationalist Party (KMT) legislator, told a US security panel yesterday. In a Taiwan contingency, cable disruption would be one of the earliest preinvasion actions and the signal that escalation had begun, he said, adding that Taiwan’s current cable repair capabilities are insufficient. The US-China Economic and Security Review Commission (USCC) yesterday held a hearing on US-China Competition Under the Sea, with Hsu speaking on
Taiwan is awaiting official notification from the US regarding the status of the Agreement on Reciprocal Trade (ART) after the US Supreme Court ruled US President Donald Trump's global tariffs unconstitutional. Speaking to reporters before a legislative hearing today, Premier Cho Jung-tai (卓榮泰) said that Taiwan's negotiation team remains focused on ensuring that the bilateral trade deal remains intact despite the legal challenge to Trump's tariff policy. "The US has pledged to notify its trade partners once the subsequent administrative and legal processes are finalized, and that certainly includes Taiwan," Cho said when asked about opposition parties’ doubts that the ART was
The US’ joint strikes with Israel on Iran dismantled a key pillar of China’s regional strategy, removing an important piece in Beijing’s potential Taiwan Strait scenario, said Zineb Riboua, a senior researcher at the Hudson Institute’s Center for Middle East Peace and Security. In an article titled: “The Iran Question Is All About China,” Riboua said that understanding the Iran issue in the context of China’s “grand strategy” is essential to fully grasp the complexity of the situation. Beijing has spent billions of dollars over the years turning Iran into a “structural strategic asset,” diverting US military resources in the
RSS